BG105666A - Complex of ras-farnesyltransferase inhibitor and sulfobutylether-7-beta-cyclodextrin or 2-hydroxypropyl-beta-cyclodextrin and method for forming the complex - Google Patents
Complex of ras-farnesyltransferase inhibitor and sulfobutylether-7-beta-cyclodextrin or 2-hydroxypropyl-beta-cyclodextrin and method for forming the complexInfo
- Publication number
- BG105666A BG105666A BG105666A BG10566601A BG105666A BG 105666 A BG105666 A BG 105666A BG 105666 A BG105666 A BG 105666A BG 10566601 A BG10566601 A BG 10566601A BG 105666 A BG105666 A BG 105666A
- Authority
- BG
- Bulgaria
- Prior art keywords
- complex
- cyclodextrin
- beta
- ras
- sulfobutylether
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Nanotechnology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11664799P | 1999-01-21 | 1999-01-21 | |
| PCT/US1999/030424 WO2000042849A1 (en) | 1999-01-21 | 1999-12-21 | COMPLEX OF RAS-FARNESYLTRANSFERASE INHIBITOR AND SULFOBUTYLETHER-7-β-CYCLODEXTRIN OR 2-HYDROXYPROPYL-β-CYCLODEXTRIN AND METHOD |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BG105666A true BG105666A (en) | 2002-04-30 |
Family
ID=22368422
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG105666A BG105666A (en) | 1999-01-21 | 2001-07-03 | Complex of ras-farnesyltransferase inhibitor and sulfobutylether-7-beta-cyclodextrin or 2-hydroxypropyl-beta-cyclodextrin and method for forming the complex |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US6218375B1 (lt) |
| EP (1) | EP1143796A4 (lt) |
| JP (1) | JP2002535253A (lt) |
| KR (1) | KR100708360B1 (lt) |
| CN (1) | CN1219517C (lt) |
| AR (1) | AR022323A1 (lt) |
| AU (1) | AU772204B2 (lt) |
| BG (1) | BG105666A (lt) |
| BR (1) | BR9916566A (lt) |
| CA (1) | CA2359646C (lt) |
| CO (1) | CO5160253A1 (lt) |
| CZ (1) | CZ20012601A3 (lt) |
| EE (1) | EE200100382A (lt) |
| GE (1) | GEP20043214B (lt) |
| HK (1) | HK1038865A1 (lt) |
| HU (1) | HUP0105160A3 (lt) |
| ID (1) | ID30139A (lt) |
| IL (1) | IL144025A (lt) |
| LT (1) | LT4893B (lt) |
| LV (1) | LV12712B (lt) |
| MY (1) | MY119700A (lt) |
| NO (1) | NO20013585L (lt) |
| NZ (1) | NZ511995A (lt) |
| PE (1) | PE20001419A1 (lt) |
| PL (1) | PL195280B1 (lt) |
| RU (1) | RU2230062C2 (lt) |
| SK (1) | SK9602001A3 (lt) |
| TR (1) | TR200102109T2 (lt) |
| TW (1) | TWI232752B (lt) |
| UA (1) | UA67825C2 (lt) |
| UY (2) | UY25987A1 (lt) |
| WO (1) | WO2000042849A1 (lt) |
| ZA (1) | ZA200104416B (lt) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI310684B (en) | 2000-03-27 | 2009-06-11 | Bristol Myers Squibb Co | Synergistic pharmaceutical kits for treating cancer |
| JP2003063965A (ja) * | 2001-06-13 | 2003-03-05 | Otsuka Pharmaceut Factory Inc | 注射用シロスタゾール水性製剤 |
| US6566347B1 (en) * | 2001-08-22 | 2003-05-20 | Duquesne University Of The Holy Ghost | Controlled release pharmaceutical |
| EP1443936A4 (en) * | 2001-11-13 | 2006-01-11 | Bristol Myers Squibb Co | PROCESS FOR THE PREPARATION OF 3,7-DISUBSTITUE-2,3,4,5-TETRAHYDRO-1H-1,4-BENZODIAZEPINE COMPOUNDS |
| KR100451485B1 (ko) | 2002-03-28 | 2004-10-06 | 주식회사종근당 | 푸마질롤 유도체 또는 그 염의 포접 화합물, 및 이를포함하는 약제학적 조성물 |
| US6869939B2 (en) * | 2002-05-04 | 2005-03-22 | Cydex, Inc. | Formulations containing amiodarone and sulfoalkyl ether cyclodextrin |
| US6818662B2 (en) * | 2002-05-28 | 2004-11-16 | Taisho Pharmaceutical Co., Ltd. | Pharmaceutical composition |
| WO2003106628A2 (en) * | 2002-06-17 | 2003-12-24 | Bristol-Myers Squibb Company | Benzodiazepine inhibitors of mitochondial f1f0 atp hydrolase and methods of inhibiting f1f0 atp hydrolase |
| US7157446B2 (en) * | 2003-05-02 | 2007-01-02 | Bristol Myers Squibb Company | Complex of ras-farnesyltransferase inhibitor, a cyclodextrin, and ethanol |
| US20070020299A1 (en) | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
| US20100204178A1 (en) | 2006-10-02 | 2010-08-12 | James Cloyd | Novel parenteral carbamazepine formulation |
| WO2007041524A2 (en) | 2005-09-30 | 2007-04-12 | Ovation Pharmaceuticals, Inc. | Novel parenteral carbamazepine formulation |
| CN100503647C (zh) * | 2005-11-02 | 2009-06-24 | 南京师范大学 | 羟丙基-磺丁基-β-环糊精及其制备方法、分析方法以及在药学上的应用 |
| TW200806284A (en) * | 2006-03-31 | 2008-02-01 | Alcon Mfg Ltd | Prenyltransferase inhibitors for ocular hypertension control and the treatment of glaucoma |
| WO2008063634A1 (en) * | 2006-11-21 | 2008-05-29 | Novartis Ag | Stable parenteral formulation containing a rsv inhibitor of a benzodiazepine structure |
| US12370352B2 (en) | 2007-06-28 | 2025-07-29 | Cydex Pharmaceuticals, Inc. | Nasal and ophthalmic delivery of aqueous corticosteroid solutions |
| CN102264736B (zh) | 2008-10-22 | 2013-08-14 | 阵列生物制药公司 | 作为TRK激酶抑制剂的取代的吡唑并[1,5-a]嘧啶化合物 |
| MX338405B (es) * | 2010-05-26 | 2016-04-14 | Neurophyxia B V | Formulaciones de 2-iminobiotina y sus usos. |
| WO2012034038A2 (en) * | 2010-09-09 | 2012-03-15 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Dual inhibitors of farnesyltransferase and geranylgeranyltransferase i |
| RU2632097C2 (ru) * | 2011-10-07 | 2017-10-02 | ПАЙСИЗ ТЕРАПЬЮТИКЗ ЭлЭлСи | Лечение злокачественных и незлокачественных заболеваний с помощью антагонистов ras |
| CN105194685A (zh) * | 2015-10-15 | 2015-12-30 | 重庆大学 | 磺胺脒的磺丁基醚-β-环糊精包合物及其粉针制剂 |
| US10525039B2 (en) | 2015-12-16 | 2020-01-07 | Neurophyxia B.V. | 2-iminobiotin for use in the treatment of brain cell injury |
| UA125025C2 (uk) | 2016-04-04 | 2021-12-29 | Локсо Онколоджі, Інк. | Способи лікування дитячих ракових захворювань |
| UA125026C2 (uk) | 2016-04-04 | 2021-12-29 | Локсо Онколоджі, Інк. | РІДКІ КОМПОЗИЦІЇ (S)-N-(5-((R)-2-(2,5-ДИФТОРФЕНІЛ)ПІРОЛІДИН-1-ІЛ)ПІРАЗОЛО[1,5-a]ПІРИМІДИН-3-ІЛ)-3-ГІДРОКСИПІРОЛІДИН-1-КАРБОКСАМІДУ |
| MX392604B (es) | 2016-05-18 | 2025-03-24 | Array Biopharma Inc | Procesos para la preparacion de (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidin-1-carboxamida y sales del mismo. |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| US20210145816A1 (en) * | 2019-11-15 | 2021-05-20 | Cyclolab Cyclodextrin Research And Development Laboratory Ltd. | Pharmaceutical formulation of lonafarnib with a sulfobutylether beta-cyclodextrin |
| AU2020414943A1 (en) | 2019-12-27 | 2022-08-04 | Wigen Biomedicine Technology (shanghai) Co., Ltd. | Spiro ring-containing quinazoline compound |
| MX2024007452A (es) * | 2021-12-15 | 2024-07-09 | Sillajen Inc | Composiciones farmaceuticas que comprenden beta-ciclodextrinas modificadas. |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5630927A (en) * | 1979-08-24 | 1981-03-28 | Zeria Shinyaku Kogyo Kk | Stabilization of guaiazulene and its derivative |
| US4371673A (en) * | 1980-07-21 | 1983-02-01 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Water soluble forms of retinoids |
| US4727064A (en) * | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
| US4596795A (en) * | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) * | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| JPH07165616A (ja) * | 1993-12-09 | 1995-06-27 | Hisamitsu Pharmaceut Co Inc | シクロデキストリンの複合組成物及び複合化法 |
| US6011029A (en) * | 1996-02-26 | 2000-01-04 | Bristol-Myers Squibb Company | Inhibitors of farnesyl protein transferase |
| JPH1067639A (ja) * | 1996-08-26 | 1998-03-10 | Shiseido Co Ltd | ビタミンｅ−ビタミンｃリン酸ジエステル／シクロデキストリン包接物及び該包接物を配合した皮膚外用剤 |
-
1999
- 1999-12-21 AU AU23740/00A patent/AU772204B2/en not_active Ceased
- 1999-12-21 NZ NZ511995A patent/NZ511995A/en unknown
- 1999-12-21 RU RU2001118265/04A patent/RU2230062C2/ru not_active IP Right Cessation
- 1999-12-21 HK HK02100115.8A patent/HK1038865A1/zh unknown
- 1999-12-21 PL PL99366338A patent/PL195280B1/pl not_active IP Right Cessation
- 1999-12-21 SK SK960-2001A patent/SK9602001A3/sk unknown
- 1999-12-21 WO PCT/US1999/030424 patent/WO2000042849A1/en not_active Ceased
- 1999-12-21 CA CA002359646A patent/CA2359646C/en not_active Expired - Fee Related
- 1999-12-21 HU HU0105160A patent/HUP0105160A3/hu unknown
- 1999-12-21 BR BR9916566-0A patent/BR9916566A/pt not_active Application Discontinuation
- 1999-12-21 ID IDW00200101596A patent/ID30139A/id unknown
- 1999-12-21 KR KR1020017009131A patent/KR100708360B1/ko not_active Expired - Fee Related
- 1999-12-21 TR TR2001/02109T patent/TR200102109T2/xx unknown
- 1999-12-21 CZ CZ20012601A patent/CZ20012601A3/cs unknown
- 1999-12-21 GE GEAP19995955A patent/GEP20043214B/en unknown
- 1999-12-21 JP JP2000594323A patent/JP2002535253A/ja active Pending
- 1999-12-21 EE EEP200100382A patent/EE200100382A/xx unknown
- 1999-12-21 UA UA2001085843A patent/UA67825C2/uk unknown
- 1999-12-21 EP EP99967470A patent/EP1143796A4/en not_active Withdrawn
- 1999-12-21 IL IL14402599A patent/IL144025A/en not_active IP Right Cessation
- 1999-12-21 CN CNB998157074A patent/CN1219517C/zh not_active Expired - Fee Related
- 1999-12-31 MY MYPI99005834A patent/MY119700A/en unknown
-
2000
- 2000-01-14 TW TW089100557A patent/TWI232752B/zh not_active IP Right Cessation
- 2000-01-17 US US09/483,840 patent/US6218375B1/en not_active Expired - Lifetime
- 2000-01-18 CO CO00002434A patent/CO5160253A1/es unknown
- 2000-01-20 AR ARP000100255A patent/AR022323A1/es unknown
- 2000-01-21 UY UY25987A patent/UY25987A1/es not_active Application Discontinuation
- 2000-01-21 PE PE2000000046A patent/PE20001419A1/es not_active Application Discontinuation
- 2000-01-21 UY UY25986A patent/UY25986A1/es unknown
-
2001
- 2001-05-29 ZA ZA200104416A patent/ZA200104416B/en unknown
- 2001-06-21 LT LT2001064A patent/LT4893B/lt not_active IP Right Cessation
- 2001-07-03 BG BG105666A patent/BG105666A/xx unknown
- 2001-07-04 LV LVP-01-101A patent/LV12712B/en unknown
- 2001-07-20 NO NO20013585A patent/NO20013585L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1038865A1 (zh) | RAS-法呢基转移酶抑制物与硫丁基醚-7-β-环糊精或2-羟基丙基-β-环糊精的复合物及方法 | |
| MY118904A (en) | 4-oxo-1, 4-dihydro-3-quinolinecarboxamides as antiviral agents | |
| NL300927I1 (nl) | tivozanib of een zout of hydraat ervan, in het bijzonder het hydrochloride-monohydraat | |
| MXPA04004037A (es) | Compuestos novedosos de 1, 2, 4-de triazol. | |
| NO931433D0 (no) | 4,1-benzoksazepinderivater og deres anvendelse | |
| DK0590919T3 (da) | Terapeutiske midler mod Parkinsons sygdom | |
| BG106585A (en) | Kinase inhibitors as therapeutic agents | |
| PT1076663E (pt) | Derivados funcionalizados de alquilo e alcenilo de cadeia lateral de glicinamidas como inibidores de farnesil transferase | |
| GB2369360A (en) | 5-cyano-2-aminopyrimidine derivatives | |
| HUP9802822A2 (hu) | Halogén-benzimidazol-származékok, intermedierjeik, előállításuk és a vegyületeket hatóanyagként tartalmazó mikrobicid készítmények | |
| IL148498A0 (en) | Quinazoline derivatives | |
| GB9908410D0 (en) | Pyridines | |
| WO2004020430A3 (fr) | Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique | |
| NO934792D0 (no) | Xantinderivater | |
| PL341050A1 (en) | Heterocyclic cytoxic agents | |
| YU21100A (sh) | Izohinolini kao urokinazni inhibitori | |
| AR044175A1 (es) | Compuestos de cefemo | |
| TW427993B (en) | New cephem compounds | |
| MXPA02003952A (es) | Derivados de imidazol como inhibidores de la fosfodieterasa vii. | |
| MY109714A (en) | Process for preparing 8-chloroquinolone derivatives | |
| EP0315434A3 (en) | Pyridoxal hydrazone derivatives their production and use and pharmaceutical compositions containing the same | |
| BG106048A (en) | 6-[[(aryl and heteroaryl)oxy]methyl]naphthalene-2-carboximidamide derivatives, preparation and therapeutic application thereof | |
| AU2002244985A1 (en) | Thiazolidinedione derivatives and pharmaceutical composition comprising the same | |
| WO2002033216A3 (en) | Corrosion inhibitor-drag reducer combinations | |
| ECSP003322A (es) | COMPLEJO DEL INHIBIDOR DE RAS- FARNESIL TRANSFERASA Y SULFOBUTILETER -7-ß- CICLODEXTRINA O 2- HIDROXIPROPIL - ß - CICLODEXTRINA Y METODO |